ci 994 and Neutropenia
ci 994 has been researched along with Neutropenia in 1 studies
tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " There are several strategies for increasing dose intensity, one being a protracted daily dosing strategy without major dose reduction for toxicity." | 1.31 | Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. ( Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE, 2000) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Keyes, KA | 1 |
| Albella, B | 1 |
| LoRusso, PM | 1 |
| Bueren, JA | 1 |
| Parchment, RE | 1 |
Other Studies
1 other study available for ci 994 and Neutropenia
| Article | Year |
|---|---|
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 2000 |